Jaguar Health, Inc. 8-K

What Happened
Jaguar Health, Inc. (JAGX) announced it entered into securities purchase agreements on January 5, 2026 and issued $350,000 aggregate principal amount of unsecured promissory notes to two accredited investors. The company said proceeds will be used for working capital and other general corporate purposes. The transaction closed on January 5, 2026.

Key Details

• $350,000 aggregate principal amount of unsecured promissory notes issued to two accredited investors.
• Notes bear interest at 6.0% per annum and mature one month after issuance (maturity ~ Feb 5, 2026). Company may prepay without penalty.
• Investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share; warrants are exercisable immediately and expire on the earlier of (i) five years from issuance, (ii) a fundamental transaction, or (iii) a liquidation event.
• Filing notes this creates a direct financial obligation and involved an unregistered sale of equity securities; the forms of the note, warrant and purchase agreement are filed as exhibits to the 8-K.

Why It Matters
This is short-term debt financing: the notes are small in size, carry 6% interest, and mature in one month, so the company will need to repay or refinance quickly. The attached warrants could lead to the issuance of up to 350,000 shares if exercised at $1.00, which can dilute existing shareholders. Retail investors should note the immediate cash boost for working capital, the short repayment timeline, and the potential equity dilution from the warrants.